Biomedical Engineering Reference
In-Depth Information
6.
REFERENCES
1. Silverberg E, Boring CC, Squires TS. 1990. Cancer statistics, 1990 [see comments].
CA
Cancer J Clin
40
:9-26.
2. Abbas F, Scardino PT. 1997. The natural history of clinical prostate carcinoma [editorial;
comment].
Cancer
80
:827-833.
3. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. 1986.
Patterns of progression in prostate cancer.
Lancet
1
:60-63.
4. Garfinkel L, Mushinski M. 1994. Cancer incidence, mortality and survival: trends in four
leading sites.
Stat Bull Metrop Insur Co
75
:19-27.
5. Terris MK, McNeal JE, Stamey TA. 1992. Estimation of prostate cancer volume by transrectal
ultrasound imaging.
JUrol
147
:855-857.
6. Guinan P, Bhatti R, Ray P. 1987. An evaluation of prostate specific antigen in prostatic cancer.
JUrol
137
:686-689.
7. Drago JR, Badalament RA, Wientjes MG, Smith JJ, Nesbitt JA, York JP, Ashton JJ, Neff JC.
1989. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis
and management of adenocarcinoma of prostate: Ohio State University experience.
Urology
34
:187-192.
8. Benson MC. 1994. Prostate specific antigen [editorial comment].
JUrol
152
:2046-2048.
9. Waterhouse RL, Resnick MI. 1989. The use of transrectal prostatic ultrasonography in the
evaluation of patients with prostatic carcinoma.
JUrol
141
:233-239.
10. Kirby RS. 1997. Pre-treatment staging of prostate cancer:
recent advances and future
prospects.
Prostate Cancer Prostatic Dis
1
:2-10.
11. RifkinMD. 1997.
Ultrasound of the prostate: imaging in the diagnosis and therapy of prostatic
disease
, 2d ed. Philadelphia: Lippincott-Raven.
12. Mettlin C, Jones GW, Murphy GP. 1993. Trends in prostate cancer care in the United States,
1974-1990: observations from the patient care evaluation studies of the American College of
Surgeons Commission on Cancer.
CA Cancer J Clin
43
:83-91.
13. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, Miller
HC, Oesterling JE, Resnick MI, Smalley SR. 1995. Prostate cancer clinical guidelines panel
summary report on the management of clinically localized prostate cancer: The American
Urological Association.
JUrol
154
:2144-2148.
14. Shinohara K, Scardino PT, Carter SS, Wheeler TM. 1989. Pathologic basis of the sonographic
appearance of the normal and malignant prostate.
Urol Clin North Am
16
:675-691.
15. Lee F, Torp-Pedersen ST, McLeary RD. 1989. Diagnosis of prostate cancer by transrectal
ultrasound.
Urol Clin North Am
16
:663-673.
16. Pouliot J, Taschereau R, Cote C. 1999. Dosimetric aspects of permanents radioactive implants
for the treatment of prostate cancer.
Phys Can
55
:61-68.
17. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. 1995. Dosimetry
of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy
Committee Task Group No. 43, American Association of Physicists in Medicine [published
erratum appears in
Med Phys
1996
23
(9):1579].
Med Phys
22
:209-234.
18. Edmundson GK, Yan D, Martinez AA. 1995. Intraoperative optimization of needle placement
and dwell times for conformal prostate brachytherapy.
Int J Radiat Oncol Biol Phys
33
:1257-
1263.
19. Downey DB, Fenster A. 1995. Three-dimensional power Doppler detection of prostate cancer
[letter].
AJR
165
:741.
20. Onik GM, Downey DB, Fenster A. 1996. Three-dimensional sonographically monitored
cryosurgery in a prostate phantom.
J Ultrasound Med
15
:267-270.
